These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38134623)

  • 1. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.
    Tieu J; Cheah JT; Black RJ; Christensen R; Ghosh N; Richards P; Robson J; Shea B; Simon LS; Singhi JA; Tugwell P; Boers M; Garibay MAA; Campochiaro C; Decary S; de Witt M; Fernandez AP; Keen HI; King L; Hinojosa-Azaola A; Hofstetter C; Gaydukova I; George MD; Gupta L; Lyne S; Makol A; Mukhtyar C; Oo WM; Petri M; Pisaniello HL; Sattui SE; Russell O; Teixeira V; Toupin-April K; Uhunmwangho C; Whitstock M; Yip K; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2021 Oct; 51(5):1139-1145. PubMed ID: 34253398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets.
    Maxwell LJ; Jones C; Bingham CO; Boers M; Boonen A; Choy E; Christensen R; Conaghan PG; D'Agostino MA; Doria AS; Grosskleg S; Hill CL; Hofstetter C; Horgan B; Kroon F; Leung YY; Mackie S; Meara A; Shea BJ; Simon LS; Touma Z; Tugwell P; Wells GA; Beaton DE
    Semin Arthritis Rheum; 2024 Jun; 66():152423. PubMed ID: 38460282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials.
    Décary S; de Wit M; Naye F; Barton JL; Fraenkel L; Li LC; Brooks P; Stacey D; Maxwell LJ; Campbell W; Hofstetter C; Voshaar M; Meara A; Christensen R; Boonen A; Suarez-Almazor ME; Meade T; March L; Jull JE; Alten R; Morgan EM; Stewart Hazlewood G; Barber CEH; Guillemin F; El-Miedany Y; Mittoo S; Robertson TW; Bartlett SJ; Singh JA; Mannion M; Nasef SI; Boel A; Adebajo A; Arnaud L; Gill TK; Moholt E; Burt J; Jayatilleke A; Hmamouchi I; Berthelsen DB; Blanco FJ; Mather K; Maharaj A; Sharma S; Caso F; Beaton D; Shea B; Fong C; Fernandez AP; Mackie S; Nikiphorou E; Jones A; Greer-Smith R; Sloan VS; Akpabio A; Strand V; Lee RR; Umaefulam V; Monti S; Abaza N; Schultz G; Stones S; Gossec L; Nielsen SM; Cavallo S; Srinivasalu H; Constien D; Evans V; Tugwell P; Toupin-April K
    Semin Arthritis Rheum; 2024 Apr; 65():152381. PubMed ID: 38306813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments.
    Naye F; Toupin-April K; de Wit M; LeBlanc A; Dubois O; Boonen A; Barton JL; Fraenkel L; Li LC; Stacey D; March L; Barber CEH; Hazlewood GS; Guillemin F; Bartlett SJ; Berthelsen DB; Mather K; Arnaud L; Akpabio A; Adebajo A; Schultz G; Sloan VS; Gill TK; Sharma S; Scholte-Voshaar M; Caso F; Nikiphorou E; Nasef SI; Campbell W; Meara A; Christensen R; Suarez-Almazor ME; Jull JE; Alten R; Morgan EM; El-Miedany Y; Singh JA; Burt J; Jayatilleke A; Hmamouchi I; Blanco FJ; Fernandez AP; Mackie S; Jones A; Strand V; Monti S; Stones SR; Lee RR; Nielsen SM; Evans V; Srinivasalu H; Gérard T; Demers JL; Bouchard R; Stefan T; Dugas M; Bergeron F; Beaton D; Maxwell LJ; Tugwell P; Décary S
    Semin Arthritis Rheum; 2024 Apr; 65():152344. PubMed ID: 38232625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.
    Kelly A; Tong A; Tymms K; March L; Craig JC; De Vera M; Evans V; Hassett G; Toupin-April K; van den Bemt B; Teixeira-Pinto A; Alten R; Bartlett SJ; Campbell W; Dawson T; Gill M; Hebing R; Meara A; Nieuwlaat R; Shaw Y; Singh JA; Suarez-Almazor M; Sumpton D; Wong P; Christensen R; Beaton D; de Wit M; Tugwell P;
    Trials; 2018 Mar; 19(1):204. PubMed ID: 29587864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders.
    Ramiro S; Page MJ; Whittle SL; Huang H; Verhagen AP; Beaton DE; Richards P; Voshaar M; Shea B; van der Windt DA; Kopkow C; Lenza M; Jain NB; Richards B; Hill C; Gill TK; Koes B; Foster NE; Conaghan PG; Smith T; Malliaras P; Roe Y; Gagnier JJ; Buchbinder R
    J Rheumatol; 2019 Aug; 46(8):969-975. PubMed ID: 30709947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing an Outcome Measures in Rheumatology (OMERACT) Core set of Outcome Measures for FOot and ankle disorders in RheumaTic and musculoskeletal diseases (COMFORT): core domain set study protocol.
    Chapman LS; Redmond AC; Flurey CA; Richards P; Smith TO; Arnold JB; Beaton D; Conaghan PG; Golightly YM; Hannan MT; Hofstetter C; Maxwell LJ; Menz HB; Shea B; Tugwell P; Helliwell P; Siddle HJ
    Trials; 2023 Jan; 24(1):65. PubMed ID: 36709309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2.
    Maxwell LJ; Beaton DE; Boers M; D'Agostino MA; Conaghan PG; Grosskleg S; Shea BJ; Bingham Iii CO; Boonen A; Christensen R; Choy E; Doria AS; Hill CL; Hofstetter C; Kroon FP; Leung YY; Mackie S; Meara A; Touma Z; Tugwell P; Wells GA
    Semin Arthritis Rheum; 2021 Dec; 51(6):1320-1330. PubMed ID: 34544617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Preliminary Core Domain Set for Clinical Trials of Shoulder Disorders: A Report from the OMERACT 2016 Shoulder Core Outcome Set Special Interest Group.
    Buchbinder R; Page MJ; Huang H; Verhagen AP; Beaton D; Kopkow C; Lenza M; Jain NB; Richards B; Richards P; Voshaar M; van der Windt D; Gagnier JJ;
    J Rheumatol; 2017 Dec; 44(12):1880-1883. PubMed ID: 28089972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.
    Toupin-April K; Barton JL; Fraenkel L; Meara A; Li LC; Brooks P; de Wit M; Stacey D; Légaré F; Shea B; Lyddiatt A; Hofstetter C; Christensen R; Scholte Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Karuranga S; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Beaton D; El-Miedany Y; Mittoo S; Bartlett SJ; Singh JA; Tugwell PS
    J Rheumatol; 2019 Oct; 46(10):1409-1414. PubMed ID: 30709963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group.
    Cheah JTL; Black RJ; Robson JC; Navarro-Millán IY; Young SR; Richards P; Beard S; Simon LS; Goodman SM; Mackie SL; Hill CL
    J Rheumatol; 2019 Sep; 46(9):1179-1182. PubMed ID: 30647165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining patient perception of overall well-being and disease activity in the OMERACT Juvenile Idiopathic Arthritis (JIA) core domain set: A report from the JIA working group.
    Balay-Dustrude E; Christensen R; Consolaro A; Ingrid Goh Y; Gottlieb BS; Horgan B; Horonjeff J; Maxwell LJ; Munro J; Pan N; Schultz G; Swart JF; Toupin-April K; Morgan EM
    Semin Arthritis Rheum; 2024 Feb; 64():152340. PubMed ID: 38071831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.
    Helliwell T; Brouwer E; Pease CT; Hughes R; Hill CL; Neill LM; Halls S; Simon LS; Mallen CD; Boers M; Kirwan JR; Mackie SL
    J Rheumatol; 2016 Jan; 43(1):182-6. PubMed ID: 26568595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.
    Toupin-April K; Décary S; de Wit M; Meara A; Barton JL; Fraenkel L; Li LC; Brooks P; Shea B; Stacey D; Légaré F; Lydiatt A; Hofstetter C; Proulx L; Christensen R; Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Guillemin F; Beaton D; El-Miedany Y; Mittoo S; Westrich Robertson T; Bartlett SJ; Singh JA; Mannion M; Nasef SI; de Souza S; Boel A; Adebajo A; Arnaud L; Gill TK; Moholt E; Burt J; Jayatilleke A; Hmamouchi I; Carrott D; Blanco FJ; Mather K; Maharaj A; Sharma S; Caso F; Fong C; Fernandez AP; Mackie S; Nikiphorou E; Jones A; Greer-Smith R; Sloan VS; Akpabio A; Strand V; Umaefulam V; Monti S; Melburn C; Abaza N; Schultz K; Stones S; Kiwalkar S; Srinivasalu H; Constien D; King LK; Tugwell P
    Semin Arthritis Rheum; 2021 Jun; 51(3):593-600. PubMed ID: 33892937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
    Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
    J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a core outcome set for foot and ankle disorders in rheumatic and musculoskeletal diseases: A scoping review and report from the OMERACT 2022 foot and ankle special interest group session.
    Chapman LS; Jones J; Redmond AC; Flurey CA; Richards P; Hofstetter C; Smith TO; Arnold JB; Hannan MT; Maxwell LJ; Menz HB; Shea B; Golightly YM; Tugwell P; Beaton D; Conaghan PG; Helliwell PS; Siddle HJ
    Semin Arthritis Rheum; 2023 Aug; 61():152210. PubMed ID: 37156170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11.
    Boers M; Idzerda L; Kirwan JR; Beaton D; Escorpizo R; Boonen A; Magasi S; Sinha I; Stucki G; Tugwell P
    J Rheumatol; 2014 May; 41(5):978-85. PubMed ID: 24584922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group.
    Berthelsen DB; Simon LS; Ioannidis JPA; Voshaar M; Richards P; Goel N; Strand V; Nielsen SM; Shea BJ; Tugwell P; Bartlett SJ; Hazlewood GS; March L; Singh JA; Suarez-Almazor ME; Boers M; Stevens RM; Furst DE; Woodworth T; Leong A; Brooks PM; Flurey C; Christensen R;
    Semin Arthritis Rheum; 2023 Dec; 63():152288. PubMed ID: 37918049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.